An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
Manav Korpal,Joshua M. Korn,Xueliang Gao,Daniel P. Rakiec,David A. Ruddy,Shivang Doshi,Jing Yuan,Steve Kovats,Sunkyu Kim,Vesselina G. Cooke,John Monahan,Frank Stegmeier,Thomas M. Roberts,William R. Sellers,Wenlai Zhou,Ping Zhu +15 more
Reads0
Chats0
TLDR
It is suggested that emergence of F876L may serve as a novel biomarker for prediction of drug sensitivity, predict a "withdrawal" response to MDV3100, and be suitably targeted with other antiandrogens or CDK4/6 inhibitors.Abstract:
Castration-resistant prostate cancer (CRPC) is the most aggressive, incurable form of prostate cancer. MDV3100 (enzalutamide), an antagonist of the androgen receptor (AR), was approved for clinical use in men with metastatic CRPC. Although this compound showed clinical efficacy, many initial responders later developed resistance. To uncover relevant resistant mechanisms, we developed a model of spontaneous resistance to MDV3100 in LNCaP prostate cancer cells. Detailed characterization revealed that emergence of an F876L mutation in AR correlated with blunted AR response to MDV3100 and sustained proliferation during treatment. Functional studies confirmed that ARF876L confers an antagonist-to-agonist switch that drives phenotypic resistance. Finally, treatment with distinct antiandrogens or cyclin-dependent kinase (CDK)4/6 inhibitors effectively antagonized ARF876L function. Together, these findings suggest that emergence of F876L may (i) serve as a novel biomarker for prediction of drug sensitivity, (ii) predict a “withdrawal” response to MDV3100, and (iii) be suitably targeted with other antiandrogens or CDK4/6 inhibitors.
Significance: We uncovered an F876L agonist-switch mutation in AR that confers genetic and phenotypic resistance to the antiandrogen drug MDV3100. On the basis of this finding, we propose new therapeutic strategies to treat patients with prostate cancer presenting with this AR mutation. Cancer Discov; 3(9); 1030–43. ©2013 AACR .
See related commentary by Nelson and Yegnasubramanian, [p. 971][1]
This article is highlighted in the In This Issue feature, [p. 953][2]
[1]: /lookup/volpage/3/971?iss=9
[2]: /lookup/volpage/3/953?iss=9read more
Citations
More filters
Journal ArticleDOI
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Hui Gao,Joshua M. Korn,Stephane Ferretti,John Monahan,Youzhen Wang,Mallika Singh,Mallika Singh,Chao Zhang,Chao Zhang,Christian Schnell,Guizhi Yang,Yun Zhang,O. Alejandro Balbin,Stephanie Barbe,Hongbo Cai,Fergal Casey,Susmita Chatterjee,Derek Y. Chiang,Shannon Chuai,Shawn Cogan,Scott D. Collins,Ernesta Dammassa,Nicolas Ebel,Millicent Embry,John Green,Audrey Kauffmann,Colleen Kowal,Rebecca Leary,Joseph Lehar,Ying Liang,Alice Loo,Edward Lorenzana,E. Robert McDonald,Margaret E. McLaughlin,Jason Merkin,Ronald Meyer,Tara L. Naylor,Montesa Patawaran,Anupama Reddy,Anupama Reddy,Claudia Roelli,David A. Ruddy,Fernando Salangsang,Francesca Santacroce,Angad P Singh,Yan Tang,Walter Tinetto,Sonja Tobler,Roberto Velazquez,Kavitha Venkatesan,Fabian Von Arx,Hui Qin Wang,Zongyao Wang,Marion Wiesmann,Daniel Wyss,Fiona Xu,Hans Bitter,Peter Atadja,Emma Lees,Francesco Hofmann,En Li,Nicholas Keen,Robert Cozens,Michael Rugaard Jensen,Nancy Pryer,Nancy Pryer,Juliet Williams,William R. Sellers +67 more
TL;DR: The results suggest that PCTs may represent a more accurate approach than cell line models for assessing the clinical potential of some therapeutic modalities and could potentially improve preclinical evaluation of treatmentmodalities and enhance the ability to predict clinical trial responses.
Journal ArticleDOI
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson,Yi-Mi Wu,Pankaj Vats,Fengyun Su,Robert J. Lonigro,Xuhong Cao,Shanker Kalyana-Sundaram,Rui Wang,Yu Ning,Lynda Hodges,Amy Gursky,Javed Siddiqui,Scott A. Tomlins,Sameek Roychowdhury,Kenneth J. Pienta,Scott Y. H. Kim,J. Scott Roberts,James M. Rae,Catherine Van Poznak,Daniel F. Hayes,Rashmi Chugh,Lakshmi P. Kunju,Moshe Talpaz,Anne F. Schott,Arul M. Chinnaiyan +24 more
TL;DR: Five new LBD-localized ESR1 mutations identified here were shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro, suggesting that activating mutations in E SR1 are a key mechanism in acquired endocrine resistance in breast cancer therapy.
Journal ArticleDOI
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Vivek K. Arora,Emily Schenkein,Rajmohan Murali,Sumit K. Subudhi,John Wongvipat,Minna D. Balbas,Neel Shah,Ling Cai,Eleni Efstathiou,Chris Logothetis,Deyou Zheng,Charles L. Sawyers,Charles L. Sawyers +12 more
TL;DR: This work identifies induction of glucocorticoid receptor (GR) expression as a common feature of drug-resistant tumors in a credentialed preclinical model and establishes a mechanism of escape from AR blockade through expansion of cells primed to drive AR target genes via an alternative nuclear receptor upon drug exposure.
Journal ArticleDOI
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
Hyo-eun C. Bhang,David A. Ruddy,Viveksagar Krishnamurthy Radhakrishna,Justina X. Caushi,Rui Zhao,Matthew M Hims,Angad P Singh,Iris Kao,Daniel P. Rakiec,Pamela Shaw,Marissa Balak,Alina Raza,Elizabeth Ackley,Nicholas Keen,Michael R. Schlabach,Michael Palmer,Rebecca Leary,Derek Y. Chiang,William R. Sellers,Franziska Michor,Vesselina G. Cooke,Joshua M. Korn,Frank Stegmeier +22 more
TL;DR: It is suggested that resistant clones are present before treatment, which would make up-front therapeutic combinations that target non-overlapping resistance a preferred approach and ClonTracer barcoding may be a valuable tool for optimizing therapeutic regimens with the goal of curative combination therapies for cancer.
Journal ArticleDOI
Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer
Arun Azad,Stanislav Volik,Alexander W. Wyatt,Anne Haegert,Stephane Le Bihan,Robert H. Bell,Shawn Anderson,Brian McConeghy,Robert Shukin,Jenny Bazov,Jack F. Youngren,Pamela L. Paris,George Thomas,Eric J. Small,Yuzhuo Wang,Yuzhuo Wang,Martin E. Gleave,Martin E. Gleave,Colin Collins,Colin Collins,Kim N. Chi,Kim N. Chi +21 more
TL;DR: The data illustrate that genomic analysis of cfDNA is a minimally invasive method for interrogating mechanisms of therapeutic resistance in mCRPC and suggest that novel agents targeting the androgen–androgen receptor (AR) axis have altered the treatment paradigm.
References
More filters
Journal ArticleDOI
Cancer statistics, 2010
TL;DR: The American Cancer Society as mentioned in this paper estimated the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data regarding cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from National Center for Health Statistics.
Journal ArticleDOI
Cancer statistics, 2008.
Ahmedin Jemal,Rebecca L. Siegel,Elizabeth Ward,Yongping Hao,Jiaquan Xu,Taylor Murray,Michael J. Thun +6 more
TL;DR: This report examines cancer incidence, mortality, and survival by site, sex, race/ethnicity, education, geographic area, and calendar year, as well as the proportionate contribution of selected sites to the overall trends.
Journal ArticleDOI
Molecular determinants of resistance to antiandrogen therapy
Charlie D. Chen,Derek S. Welsbie,Chris Tran,Sung Hee Baek,Randy Chen,Robert L. Vessella,Michael G. Rosenfeld,Charles L. Sawyers +7 more
TL;DR: Using microarray-based profiling of isogenic prostate cancer xenograft models, it is found that a modest increase in androgen receptor mRNA was the only change consistently associated with the development of resistance to antiandrogen therapy.
Journal ArticleDOI
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran,Samedy Ouk,Nicola J. Clegg,Yu Chen,Philip A. Watson,Vivek K. Arora,John Wongvipat,Peter Smith-Jones,Dongwon Yoo,Andrew Kwon,Teresa Wasielewska,Derek S. Welsbie,Charlie D. Chen,Celestia S. Higano,Tomasz M. Beer,David T. Hung,Howard I. Scher,Michael E. Jung,Charles L. Sawyers +18 more
TL;DR: The diarylthiohydantoins RD162 and MDV3100 are characterized, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression that appear to be promising candidates for treatment of advanced prostate cancer.
Journal ArticleDOI
Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
TL;DR: Strategies that are focused on the androgen receptor either directly or indirectly, as single agents or in combination, that are in clinical development that are discussed are discussed.
Related Papers (5)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher,Karim Fizazi,Fred Saad,Mary-Ellen Taplin,Cora N. Sternberg,Kurt Miller,Ronald de Wit,Peter F.A. Mulders,Kim N. Chi,Neal D. Shore,Andrew J. Armstrong,Thomas W. Flaig,Aude Flechon,Paul N. Mainwaring,Mark D. Fleming,John D. Hainsworth,Mohammad Hirmand,Bryan Selby,Lynn Seely,Johann S. de Bono,B Ch +20 more
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Emmanuel S. Antonarakis,Changxue Lu,Hao Wang,Brandon Luber,Mary Nakazawa,Jeffrey C. Roeser,Yan Chen,Tabrez A. Mohammad,Yi Chen,Helen L. Fedor,Tamara L. Lotan,Qizhi Zheng,Angelo M. De Marzo,John T. Isaacs,William B. Isaacs,Rosa Nadal,Channing J. Paller,Samuel R. Denmeade,Michael A. Carducci,Mario A. Eisenberger,Jun Luo +20 more
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono,Christopher J. Logothetis,Arturo Molina,Karim Fizazi,Scott North,Luis Chu,Kim N. Chi,Robert Jones,Oscar B. Goodman,Fred Saad,John Staffurth,Paul N. Mainwaring,S. J. Harland,Thomas W. Flaig,Thomas E. Hutson,Tina Cheng,Helen Patterson,John D. Hainsworth,Charles J. Ryan,Cora N. Sternberg,Susan Ellard,Aude Flechon,Mansoor N. Saleh,Mark C. Scholz,Eleni Efstathiou,Andrea Zivi,Diletta Bianchini,Yohann Loriot,Nicole Chieffo,Thian Kheoh,Christopher M. Haqq,Howard I. Scher +31 more
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Tomasz M. Beer,Andrew J. Armstrong,Dana E. Rathkopf,Yohann Loriot,Cora N. Sternberg,Celestia S. Higano,Peter Iversen,Suman Bhattacharya,Joan Carles,Simon Chowdhury,Ian D. Davis,Johann S. de Bono,Christopher P. Evans,Karim Fizazi,Anthony M. Joshua,Choung-Soo Kim,Go Kimura,Paul N. Mainwaring,Harry H. Mansbach,Kurt Miller,Sarah B. Noonberg,Frank Perabo,De Phung,Fred Saad,Howard I. Scher,Mary-Ellen Taplin,Peter Venner,Bertrand Tombal +27 more